[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371209-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371209-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-pathway-alteration-load-is-a-pan-cancer-determinant-of-outcome-of-targeted-therapies-results-from-the-drug-rediscovery-protocol-drup","The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies - results from the Drug Rediscovery Protocol (DRUP)","","Pathway alteration load (PAL) is evaluated as a biomarker for predicting the clinical benefit of targeted therapy (TT) across multiple cancer types, motivated by the idea that tumors with many altered oncogenic pathways may resist therapies that inhibit only one pathway. Results from the prospective, pan-cancer Drug Rediscovery Protocol (DRUP) trial link PAL to clinical benefit rate, progression-free survival, and overall survival, with independent validation in the Hartwig Medical database. Findings support improved TT patient selection and combinatorial strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-pathway-alteration-load-is-a-pan-cancer-determinant-of-outcome-of-targeted-therapies-results-from-the-drug-rediscovery-protocol-drup/371209/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-pathway-alteration-load-is-a-pan-cancer-determinant-of-outcome-of-targeted-therapies-results-from-the-drug-rediscovery-protocol-drup/371209.png","ImageObject",300,407,{"name":42,"@type":43},"Lucas Martin","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the pathway alteration load (PAL) and why does it matter for targeted therapies?","Question",{"text":63,"@type":64},"PAL summarizes the number of altered oncogenic signaling pathways in a patient’s tumor. It matters because a higher PAL may indicate reduced benefit from targeted therapies that act on only one pathway.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were outcomes assessed in the DRUP study?",{"text":68,"@type":64},"DRUP is a prospective, pan-cancer non-randomized trial using matched off-label targeted and immunotherapies based on an actionable molecular profile. PAL was correlated with clinical benefit rate, progression-free survival, and overall survival, and results were validated in an independent Hartwig Medical database.",{"name":70,"@type":61,"acceptedAnswer":71},"What overall conclusions were reached about using PAL to guide treatment?",{"text":72,"@type":64},"PAL emerged as a pan-cancer determinant of targeted therapy outcomes. The findings support refined patient selection for targeted therapies and provide a rationale for combinatorial treatment approaches in tumors with multiple affected pathways.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371209,1790822927,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","ORIGINAL ARTICLE  \nThe pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)  \nK. Verkerk1 , 2y, L. J. Zeverijn1, 2y, J. van de Haar1, 2, P. Roepman3, B. S. Geurts1, 2, A. C. Spiekman4 , 5, V. van der Noort6,  \nJ. M. van Berge Henegouwen2,7 , L. R. Hoes1,2 , H. van der Wijngaart 8 , A. M. L. Jansen9 , [W. W. J. de](W. W. J. de) Leng9 , A. J. Gelderblom7 ,  \nH. M. W. Verheul5 & E. E. Voest1, 2 􀀂  \n1Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam; 2Oncode Institute, Utrecht; 3Hartwig Medical Foundation, Amsterdam; 4Department of Medical Oncology, Radboud University Medical Center, Nijmegen; 5Department of Medical Oncology, Erasmus Medical Center, Rotterdam; 6Department of Biometrics, Netherlands Cancer Institute, Amsterdam; 7Department of Medical Oncology, Leiden University Medical Center, Leiden; 8Department of Medical Oncology, GROW, Maastricht University Medical Centre, Maastricht; 9Department of Pathology, University Medical Cancer Center Utrecht, Utrecht, The Netherlands  \nAvailable online xxx  \nBackground: Many patients with cancer exhibit primary or rapid secondary resistance to targeted therapy (TT) . We hypothesized that a higher number of altered oncogenic signaling pathways [pathway alteration load (PAL)] would reduce the beneﬁt of TT which only intervenes in one pathway. This hypothesis was tested in the Drug Rediscovery Protocol (DRUP) .  \nPatients and methods: DRUP is a prospective, pan-cancer, non-randomized clinical trial (NCT02925234) that treats patients with therapy-refractory metastatic cancer and an actionable molecular proﬁle using matched off-label targeted and immunotherapies. All patients treated with TT with available clinical outcomes and whole genome sequencing were included. PAL was determined based on driver gene alterations and correlated with clinical beneﬁt rate (CBR), progression-free survival (PFS) and overall survival (OS) . Outcomes were validated in the independent Hartwig Medical database of metastatic cancers.  \nResults: In 154 patients treated with TT, the median PAL was 3 . Patients with a PAL below median (n ¼ 60) demonstrated a higher CBR (41 .7% versus 25 .5%, odds ratio 0 .48, P ¼ 0.051), longer PFS [median 4 .7 versus 2 .9 months, adjusted hazard ratio (aHR) 1 .70, P ¼ 0.020] and OS (median 13 .7 versus 5 .6 months, aHR 3 .80, P \u003C 0.001) compared with those with PAL 􀀃3 . Two hundred and ﬁfty-eight patients in the Hartwig database showed similar results for CBR (54 . 2% versus 36 .7%, odds ratio 2 .04, P ¼ 0.009) and PFS (7 .0 versus 4 . 2 months, aHR 1 .55, P ¼ 0.009) . Conclusions: In our population, PAL emerged as a pan-cancer determinant of outcome to TT. Our ﬁndings support reﬁned patient selection for TT and highlight the rationale for combinatorial treatment strategies in patients with multiple affected pathways.  \nKey words: targeted therapy, oncogenic signaling pathways, metastatic cancer  \nINTRODUCTION  \nBy speciﬁcally inhibiting molecular signaling mechanisms essential for tumorigenesis and proliferation, targeted therapies (TTs) have signiﬁcantly improved response ratesand survival across several solid tumor types.1-4 However, still a considerable amount of patients who are molecularly eligible for targeted treatment do not beneﬁt from this  \n*Correspondence to: Prof. Emile E. Voest, Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel: þ31-20-512-9111  \nE-mail: [e.voest@nki.nl](e.voest@nki.nl) (E. E. Voest).  \nyContributed equally to this work.  \n2059-7029/© 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \ntreatment modality, either by showing primary resistance ","cbCaieEvtFxYnqnG","https://ap.wps.com/l/cbCaieEvtFxYnqnG","pdf",570917,11,"English","# Background\n# Patients and methods\n# Results\n# Conclusions","[{\"question\":\"What is the pathway alteration load (PAL) and why does it matter for targeted therapies?\",\"answer\":\"PAL summarizes the number of altered oncogenic signaling pathways in a patient’s tumor. It matters because a higher PAL may indicate reduced benefit from targeted therapies that act on only one pathway.\"},{\"question\":\"How were outcomes assessed in the DRUP study?\",\"answer\":\"DRUP is a prospective, pan-cancer non-randomized trial using matched off-label targeted and immunotherapies based on an actionable molecular profile. PAL was correlated with clinical benefit rate, progression-free survival, and overall survival, and results were validated in an independent Hartwig Medical database.\"},{\"question\":\"What overall conclusions were reached about using PAL to guide treatment?\",\"answer\":\"PAL emerged as a pan-cancer determinant of targeted therapy outcomes. The findings support refined patient selection for targeted therapies and provide a rationale for combinatorial treatment approaches in tumors with multiple affected pathways.\"}]","The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies - results from the Drug Rediscovery Protocol (DRUP) | PDF",1790191525,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35ea0d27c4d212e0a33f925dce22ea3c.webp",983,1269,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91c7e7bf20395ff196669b266fa12e08.webp",982,1268,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c403c7d444c9762e31b2e72aebf92c14.webp",981,1266,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7290cbf10fedf6b5ef219dc3245300a.webp",980,1265]